GERD drug Esomeprazole linked with Hyperprolactinaemia, reveals IPC Drug Safety alert
The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of September, has revealed that Esomeprazole, indicated for the treatment of Gastroesophageal reflux disease (GERD), is linked with adverse drug reactions (ADRs) named Hyperprolactinaemia.
In connection to the above, the Indian Pharmacopoeia Commission (IPC) has cautioned healthcare professionals to diligently monitor the potential occurrence of Adverse Drug Reactions (ADRs) when administering Esomeprazole.
For more details, check out the link given below:
Drug Safety Alert: Indian Pharmacopoeia Commission Flags ADR Linked To GERD Drug Esomeprazole
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.